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Outcome of elective endovascular abdominal
aortic aneurysm repair in nonagenarians
Stuart B. Prenner, BS, Irene C. Turnbull, MD, Gregory W. Serrao, MS, Eric Fishman, MD,
Sharif H. Ellozy, MD, Angeliki G. Vouyouka, MD, Michael L. Marin, MD, and
Peter L. Faries, MD, New York, NY
Objective: Compared with open repair of abdominal aortic aneurysms (AAA), endovascular repair (EVAR) is associated
with decreased perioperative morbidity and mortality in a standard patient population. This study sought to determine
if the advantage of EVAR extends to patients aged >90 years.
Methods:This was a retrospective review from a prospectively maintained computerized database. Of the 322 patients aged
>80 treated with EVAR from January 1997 to November 2007, 24 (1.9%) were aged >90. Mean age was 91.5  1.5
years (range, 90-95 years), and 83.3% were men. Mean aneurysm size was 6.8 cm (range, 5.2-8.7 cm).
Results: Mean procedural blood loss was 490 mL (range, 100-4150 mL), and 20.8% required an intraoperative
transfusion. Mean postoperative length of stay was 6.0 days, (median, 4 days; mode, 1 day; range, 1-42 days), with 33.3%
of patients discharged on the first postoperative day. Amongst the 24 patients, there were 6 (25.0%) perioperative major
adverse events, and 2 patients died, for a perioperative mortality rate of 8.3%. Mean follow-up was 20.5 months (range,
1-49months). Overall, three patients (12.5%) required a secondary intervention, comprising thrombectomy, angioplasty,
and proximal cuff extension. No patients required conversion to open repair. Two patients (8.3%) died of AAA rupture
at 507 and 1254 days. Freedom from all-cause mortality was 83.3% at 1 year and 19.3% at 5 years. Freedom from
aneurysm-related mortality was 87.5% at 1 year and 73.2% at 5 years. Endoleak occurred in five patients (20.8%), with
three type I and two of indeterminate type; of these, two patients with type I endoleak underwent secondary intervention
at 153 and 489 days after EVAR, of which one case was successful.
Conclusion: Our study supports that EVAR in nonagenarians is associated with acceptable procedural success and
perioperative morbidity and mortality. The medium-term results suggest that EVAR may be of limited benefit in very
carefully selected patients who are aged >90 years. ( J Vasc Surg 2011;54:287-94.)
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iAs life expectancy continues to increase, the number of
nonagenarians is now greater than ever. In the United
States, individuals aged 85 years currently represent the
fastest growing demographic of the population and are ex-
pected to nearly double in number from 4 to 7 million from
2000 to 2020.1 Furthermore, the average life expectancy of
those reaching 90 in the general population is nearly 4 years.2
As an age-related disease, abdominal aortic aneurysms (AAA)
are increasing in prevalence in this demographic.
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doi:10.1016/j.jvs.2010.12.046Nonagenarians are uniformly considered to be a “high
isk” population by virtue of both age and high rates of
omorbidities, and are often not considered candidates for
pen repair.3 Although endovascular repair of AAAs
EVAR) has become an increasingly used approach, EVAR
n older patients has been independently associated with
igher perioperative and long-term morbidity and mortal-
ty compared with younger patients.3-5 Many recent studies
ave focused on the benefits of EVAR in the high-risk
atient, but age is only one of several criteria used to define
igh risk.6-10 Studies looking at outcomes specifically in the
ldest of patients undergoing EVAR are largely lacking.
he purpose of this study was to determine if the advantage
f EVAR extends to nonagenarians.
ETHODS
This study was a subset analysis of a previously pub-
ished retrospective review of a prospectively collected
atabase from our institution. The study was approved
y the institution’s Internal Review Board. The study
ncluded patients who underwent elective EVAR be-
ween January 1997 and November 2007 and were aged
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August 2011288 Prenner et al90 years at the time of the procedure. All EVAR
procedures were performed at the Mount Sinai Hospital,
New York, NY. Patients were excluded if they had un-
dergone a previous EVAR at age 90. Primary and
secondary end points were reported according to previ-
ously published guidelines.11
Preoperative aneurysm size and anatomic characteris-
tics were determined with computed tomography (CT)
angiography. Postoperatively, patients were followed-up at
1, 6, and 12 months, and annually thereafter. The standard-
ized follow-up protocol included physical examination,
helical CT angiography, and plain abdominal radiographs.
Postoperative surveillance was not modified in patients with
documented renal insufficiency (serum creatinine 1.5
mg/dL). At time of EVAR, patients with renal insufficiency
were given N-acetylcysteine before and after the proce-
dures, as well as pretreatment with intravenous hydration.
Endoleaks were detected by CT scan and were consid-
ered primary if they occurred within the perioperative pe-
riod (30 days), and otherwise, as secondary endoleaks.
Given that this series dates back to the late 1990s, the
quality of CT imaging did vary considerably during this
10-year period. In freedom from endoleak analysis, events
were considered to be present at time of the initial endoleak
detection, regardless of subsequent change in endoleak
size.
Technical success and clinical success were also re-
ported according to previously published Society for Vas-
cular Surgery guidelines. Technical success was defined as
successful intravascular access to the aneurysm site, deploy-
ment of the stent graft with secure fixation and patency, and
absence of type I and III endoleaks within the first 24
hours. Clinical success required technical success as well as
absence of death, type I and III endoleaks, graft infection,
graft thrombosis, rupture, or conversion to open repair
30 days.11
Analysis of data was based on the intention-to-treat
principle. Results are reported as mean and standard devi-
ation. All freedom from event analyses were estimated with
the Kaplan-Meier method. The Social Security Death Reg-
istry was used to confirm date of death for patients lost to
follow-up. Patients who were not listed in the registry were
assumed to be alive for the purpose of calculating death
rate. However, all patients were removed from Kaplan-
Meier analysis at the time of the last follow-up. All statistical
analyses were conducted using SPSS software (SPSS Inc,
Chicago, Ill).
RESULTS
From a group of 322 patients aged 80 years who
underwent elective EVAR, a subgroup of 24 patients
(83.3% men) who were 90 years were included in this
study. Patients were a mean age of 91  1.5 years (range,
90-95 years). The mean follow-up time was 20.5 months
(range, 1-49 months). The mean maximum AAA diameter
was 68 10 mm (range, 52-87 mm). Only one AAA5.5
cm underwent intervention (5.2 cm). The two most fre-
quent comorbidities, hypertension and arrhythmia, af- 1ected 58.3% and 37.5% of the patients, respectively
Table I).
Regional anesthesia was used in all cases. The average
uration of the procedure was 230  73 minutes (range,
05-353 minutes). During the procedure, an average of
52 112 mL (range, 150-520 mL) of contrast was used.
he mean estimated blood loss was 491 998 mL (range,
00-4150 mL) and was 800 mL in all but one patient
Table II). Five patients (20.8%) required an intraoperative
ransfusion.
A bifurcated device was used in 87.5% of the cases and
2.5% were treated with an aortouniiliac device: 58.3%
eceived Talent grafts (Medtronic, Minneapolis, Minn),
3.3% received Gore (W. L. Gore and Assoc, Flagstaff,
riz), and 8.3% received AneuRx (Medtronic). Graft types
nd endovascular approaches both varied throughout the
able I. Preprocedural characteristics
Characteristic Outcome
Patients, No. 24
Demographics
Age, mean  SD, y 91.5  1.5
Male gender, % 83.3
Risks, %
Hypertension 58.3
Coronary artery disease 33.3
Angina 0.0
Arrhythmia 37.5
Myocardial infarction 20.8
Congestive heart failure 12.5
COPD 25.0
Hyperlipidemia 25.0
Creatinine, 1.5 mg/dL 25.0
Peripheral vascular disease 8.3
Diabetes 4.2
Stroke 4.2
Smoking 54.2
Cancer 8.3
ASA 3 83.3
ASA 4 16.7
SA, American Society of Anesthesiologists physical status classification;
OPD, chronic obstructive pulmonary disease; SD, standard deviation.
able II. Procedural details
ariablesa Outcome
rocedural characteristic, No. 24
neurysm diameter, mm 68.3  10.0 (52-87)
uration of procedure, min 230  73 (105-353)
nesthesia
Regional 24/24 (100.0)
rocedural blood loss, mL 490.63  997.92 (100-4150)
olume contrast, mL 252.50  112.03 (150-520)
ime until discharge, d 6.00  9.46 (1-42)
ime in intensive care unit 2/24 (8.3)b
ollow-up, mo 20.5 (1-49)
Continuous data are presented as the mean standard deviation (range) or
s mean (range), and categoric data are presented as No. (%).
Number of patients who spent any time in an ICU setting.0 years of this study, reflecting changes in surgeon expe-
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Volume 54, Number 2 Prenner et al 289rience. Mean postoperative length of stay was 6  9 days
(median, 4 days; range, 1-42 days), with 33.3% of patients
discharged on the first postoperative day. Two patients
required a postoperative stay in the intensive care unit. In
one patient, complications related to operative blood loss
led to colonic ischemia requiring a colostomy and mechan-
ical ventilation, and the patient ultimately died of sepsis 42
days after EVAR. A second patient required an intensive
care unit stay for myocardial infarction and ultimately died
of ventricular arrhythmia 15 days after EVAR.
The technical success rate was 91.6%. The two technical
failures included a type I endoleak that failed to resolve
despite proximal cuff extension. The second technical fail-
ure was the result of aortic perforation near the aortic
bifurcation from a bifurcated device at the time of stent
dilatation. Although open conversion was considered, fa-
vorable anatomy and stabilization with an 8-unit transfu-
sion led to continuation of the endovascular approach. The
patient was not thought to be a candidate for open repair.
No deaths occurred in the first 24 hours. The periop-
erative mortality rate was 8.3% (2 events). The first death
previously mentioned occurred in a 92-year-old man who
developed a myocardial infarction 2 days after surgery and
died 15 days after EVAR. The second death occurred in a
Fig 1. Kaplan-Meier (KM) graph documents freedom f
extension, conversion to open repair, and femoral-femor90-year-old man who developed respiratory failure after olective right hip hemiarthroplasty and died 24 days after
VAR.
Clinical success rate at 30 days was 79.2%, with periop-
rative death responsible for the greatest number of clinical
ailures (2 of 5). The overall freedom from secondary
eintervention, including coil embolization, conversion to
pen repair, distal extension, and femoral-femoral bypass,
as 91.0% at 1 year and 85.0% at 5 years (Fig 1). Three
econdary interventions included an angioplasty and a cuff
xtension for the repair of type I endoleaks and an iliofem-
econdary intervention, including coil embolization, cuff
pass.
able III. Perioperative adverse events
Complications No. %
Lower limb ischemiaa 1 4.2
Bleedingb 1 4.2
Vascular injuryc 1 4.2
Respiratory failure 2 8.3
Cerebrald 1 4.2
Lower limb ischemia includes graft thrombosis.
Bleeding includes a groin hematoma.
Vascular injury includes a perforated aorta.
Cerebral includes a postoperative transient ischemic attack.rom sral thrombectomy in a patient readmitted 11 days after
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August 2011290 Prenner et alEVAR with lower limb ischemia secondary to graft limb
occlusion.
Six independent major adverse events occurred within
the 30-day perioperative period. Previously mentioned ad-
verse events include two patients with respiratory failure,
vascular injury necessitating multiple transfusions, and
lower limb ischemia necessitating iliofemoral thrombec-
tomy. Other events included transient ischemic attack and
groin hematoma 3 weeks postoperatively that required
evacuation under general anesthesia (Table III). Overall,
12 patients (50%) had no AAA-related complications, met
technical and clinical success, and had no endoleak or
AAA-related death during the follow-up.
Freedom from AAA-related mortality was 87.5% at 1
year and 73.2% at 5 years (Fig 2). Freedom from overall
mortality was 83.3% at 1 year and 19.3% at 5 years (Fig 3).
Overall, there were five AAA-related deaths. By definition,
these included the two perioperative deaths; the other
causes of death included one patient with complications
related to aortic perforation previously mentioned, and two
ruptures that occurred at 507 and 1254 days after EVAR.
The first of two ruptures occurred in a patient with routine
surveillance and known type I endoleak who underwent
previous angioplasty and then had endoleak recurrence that
Fig 2. Kaplan-Meier (KM) graph represents freedom
including all perioperative deaths, deaths from AAA rupwas elected not to be treated. The second patient had no toutine surveillance. At the time of analysis, three nonage-
arians were still alive at an average of 5.2 years after EVAR.
The rate of freedom from endoleak was 79.7% at 1 year
nd 74.0% at 2 years (Fig 4). Endoleak occurred in five
atients (20.8%), with three cases of type I and two cases of
ndeterminate type. Two patients with type I endoleak
nderwent secondary intervention: one required cuff ex-
ension, and the other was repaired with angioplasty. The
nal type I endoleak was monitored regularly; the aneu-
ysm size remained stable and no further intervention was
aken (Table IV). There were no conversions to open repair
n the 24 patients in this study.
ISCUSSION
With the number of nonagenarians in this country
ising dramatically, the approach to treatment of AAA in
his unique population is of increasing importance. Nona-
enarians are of particular interest because both their age
nd numerous medical comorbidities make them almost
niformly unfit for open repair. Although watchful waiting
ay be a desirable option in this population, several studies
ave elucidated the natural history of untreated large AAAs.
n 2002, Lederle et al12 found 1-year rupture rates in
atients deemed unfit for surgery were 19% for AAA be-
abdominal aortic aneurysm (AAA)-related mortality,
and death due to secondary intervention.fromween 6.5 and 6.9 cm and 32.5% for AAA 7.0 cm, and
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Volume 54, Number 2 Prenner et al 291these figures are likely underestimates due to the low au-
topsy rate in their study. Conway et al13 monitored 106
patients deemed unfit for open repair. The rate of death
from AAA rupture over the 3 years of follow-up was 50% in
patients with aneurysms of 6.0 to 7.0 cm and 55% in
patients with larger aneurysms.
As a result, recent studies have sought to determine if
EVAR offers a survival advantage compared with no inter-
vention in patients unfit for open repair. The United King-
dom Endovascular Aneurysm Repair 2 (EVAR2) trial ran-
domized high-risk patients to EVAR or no intervention
and found no significant difference between EVAR and no
intervention in all-cause mortality or aneurysm-related
mortality to 4 years. The study concluded that EVAR does
not improve survival in high-risk patients. The study had
several limitations, most notably the 14 patients who were
randomized to surgery and died before intervention that
were included in the mortality estimates for the treatment
group.6 Iannelli et al14 found similar results in a 2005 study
in which high-risk patients were randomized to EVAR or
open repair. Despite differences in the perioperative death
rate between EVAR and open repair (0% and 14.3%, respec-
tively), there was no significant difference in late mortality.
Despite these initial suggestions that EVAR offers no
long-term survival benefit to high-risk patients compared
with no intervention or open repair, subsequent studies
Fig 3. Kaplan-Meier (KM) graph replooking at high-risk populations have found favorable re- nults with EVAR. EVAR has been associated with low
perative mortality of 0% to 4.3% and better long-term
utcomes, with a 4-year survival of 56% to 79%, compared
ith open repair or watchful waiting in this popula-
ion.7-10,15 However, these subsequent studies were all
onrandomized EVAR and thus represent an inferior level
f evidence.
The intraoperative mortality in our study was 0%, sim-
lar to previous studies of EVAR in high-risk populations.
lthough the perioperative mortality rose to 8.3%, one of
he two perioperative deaths occurred from complications
elated to a right hip hemiarthroplasty the patient under-
ent 3 weeks after EVAR. We report low long-term sur-
ival at 5 years of 19.3%, much lower than that of previous
tudies of high-risk patients. These long-term data suggest
hat EVAR may not be of a mortality benefit in this subset
opulation. However, it also underscores the age difference
etween the nonagenarians in this study (average age, 91
ears) and participants in all previous studies on high risk
atients, whose ages ranged from 72.6 to 77 years, nearly
4 years younger that the population in this study.
There has been no accepted standard to define “high
isk.” In a recent prospective cohort study, Mastracci et al16
dentified several independent predictors of mortality in
atients undergoing EVAR, including age, aneurysm diam-
ter, peripheral arterial disease, chronic obstructive pulmo-
ts freedom from all-cause mortality.ary disease, congestive heart failure, use of home oxygen,
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August 2011292 Prenner et aland use of salicylates. The inclusion criteria for studies on
high risk similarly often include absolute age criteria (range,
60-80 years) as well as the presence of one or more
comorbidities that place the patient at risk for general
anesthesia.7-10,15 Although the patients in this study are
similar to those in EVAR2 and other studies, the discrep-
ancy in long-term outcomes suggests that much of the
medium-term and long-term risk in nonagenarians may
result solely from reduced life expectancy.
A recent report documented a higher incidence of
aneurysmatic degeneration of the iliac vessels, increased
Fig 4. Kaplan-Meier (KM) graph represents freedom fro
of indeterminate type.
Table IV. Late outcomes at 4 years
Events No. %
Freedom from mortality
Overall 2 11.4
AAA-related 2 58.1
Overall conversion 0 0.0
Overall rupture 2 8.3
Endoleaks
Type I 3 12.5
Type II 0 0.0
Indeterminate type 2 8.3
AAA, Abdominal aortic aneurysm.tortuosity, larger aneurysm necks, and greater neck angu- pation in older patients compared with younger cohorts.3
ndeed, in this study, the high rates of type I endoleak
12.5%) and rupture (8.3%) may be related to the more
omplicated anatomy seen in nonagenarians. Additionally,
his study dates back to the early days of EVAR and includes
any first-generation devices that were not as effective at
neurysm exclusion compared with newer stents. Many of
hese early stents did not accommodate femoral access as
asily, also partially explaining the high rates of blood loss in
his study compared with other studies of EVAR. Nonage-
arians are nearly uniformly not fit for open repair; thus,
espite more hostile anatomy, the decision was made to
ttempt EVAR in the selected patients in this study.
Although EVAR is associated with decreased initial
orbidity and mortality compared with open repair, this is
alanced and may be outweighed by increased morbidity in
he long-term related largely to secondary procedures. Pre-
ious studies of EVAR have suggested that up to 27% to
5% of patients eventually required a secondary proce-
ure.17,18 In this study, three patients underwent reinter-
ention (12.5%). Some have suggested that this tradeoff
ay be worthwhile, particularly in older patients who are
ess likely to tolerate the prolonged recovery and intensive
are unit stay associated with open repair.19 Unfortunately,
econdary procedures may also be less well tolerated in this
pe I and type II endoleaks, as well as freedom from thosem tyopulation. In this study, one of the two ruptures occurred
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angioplasty and known recurrent endoleak who decided
not to pursue an additional reintervention. The patient
died 1 month later.
Finally, as a retrospective review, this study is subject to
selection bias because patients deemed unfit for EVAR
were not included in the analysis. Although it is not possible
to determine how many nonagenarians sought EVAR, the
24 patients in this study certainly represent a small minority
of all nonagenarians presenting as surgical candidates. Re-
cent analysis has estimated the cost of EVAR for the first
year to be roughly $35,000. Thus, cost-effectiveness esti-
mates largely depend on the quality of life gained by the
patient, data that were not obtained in this study.20 In one
recent report, compared with open repair, patients aged
80 who underwent EVAR had a statistically significant
more rapid return to baseline despite a lower quality of life
at 6 months.21 Preoperative and anticipated postoperative
quality of life are essential in the consideration of which
nonagenarians to intervene on.
Freedom from all-cause mortality at 5 years was only
19.3%, highlighting the natural history of this demographic.
However, at the time of publication, three nonagenarians
from this study were still alive, on average 5.2 years after
EVAR. Although the risk of rupture of a large AAA is certainly
substantial, studies comparing long-term outcomes in nona-
genarians undergoing EVAR with those treated medically are
lacking and are necessary to more accurately determine if any
survival benefit is conferred from EVAR. Additionally, be-
cause the number of nonagenarians is only increasing, analysis
of which nonagenarians are most likely to benefit from EVAR
is of paramount importance.
CONCLUSION
Our study supports that EVAR in nonagenarians is asso-
ciated with acceptable procedural success and perioperative
morbidity and mortality. However, life expectancy and quality
of life of these individuals are both of significant concern.
EVAR prevented death from AAA rupture in most individuals
with low rates of reintervention. Regional anesthesia and
reduced hospital stay may be of significant benefit to this
population. The medium-term results suggest that EVAR
may be of limited benefit in very carefully selected patients
who are aged 90 years. Additional studies are necessary to
further delineate which nonagenarians will benefit from
EVAR and to determine if any survival benefit is gained
compared with conservative management.
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As the population continues to age, vascular surgeons will
continue to be confronted with the difficult problem of treating
increasingly elderly patients. In this article, the authors address the
issue of endovascular abdominal aortic aneurysm repair (EVAR) in
nonagenarians, a population of patients clearly expected to increase
in the coming decades. The data from their report can be used to
both support and refute the wisdom of performing EVAR in
patients in their ninth decade.
Although procedural results were “acceptable,” to use the
authors’ word, perioperative morbidity (25%) and mortality (8.3%)
were much higher than what we have come to expect from EVAR
in the general population. Ultimately,20% of the patients died as
a direct result of the aneurysm or the repair, so it is not clear that
EVAR in this patient group has improved the natural history of the
disease. Furthermore, one has to question the wisdom of extend-
ing expensive health care resources to patients with limited life
expectancy, only 19% at 5 years in this study. It must always be keptuestionable whether the cost/benefit ratio pencils out in this
cenario.
On the other hand, all vascular surgeons have seen and treated
he “vigorous” nonagenarian whose health and quality of life defy
heir chronologic age. Although, as one of my mentors once told
e, they may not look 90 before their operation, they always look
0 afterward. Clearly, though, there exists a subset of nonagenar-
ans for whom EVAR is appropriate. Unfortunately, the numbers
reated in this study were not large enough to stratify patients to
etermine factors predicting good and poor outcomes. Given the
arity of this procedure in nonagenarians, it is unlikely that a single
enter would be able to do so, and pooled data from multiple
enters may be necessary to answer this question and identify
onagenarians for whom this procedure is most appropriate.
The authors are to be congratulated for critically analyzing
nd presenting their results in this difficult group of patients. The
onclusions are open to debate, and this article does not provide a
efinitive answer; however, it does serve as a point of comparison
or future studies that address this issue.
